Underpinning Voyager’s mission is its trademark AAV capsid-discovery platform, Tropism Redirection of AAV ... at comparable levels in both NHPs and mice. “This cross-species functionality ...

A common in the field is that the tropism of a particular AAV serotype can differ across species. AAVs engineered to target particular cells following systemic delivery in mice, for instance ...

According to Carter, the company is seeking to overcome these challenges through their TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform.

Researchers prefer AAV vectors due to their broad tissue tropism, high safety profile, and adaptability in manufacturing procedures. In the present review, researchers explored AAV-vectored ...

A second presentation will share new preclinical data, demonstrating MSH3 knockdown via an artificial miRNA packaged in our novel AAV-DB-3 capsid, in a mouse model of HD. The knockdown achieved in ...